Sep 1, 2022 · Eight patients (67%) had mutations in BTK or PLCG2 associated with resistance to BTKi. BCL2 mutations were not tested in this cohort.

Feb 3, 2025 · In the relapsed or refractory setting, the BRUIN CLL-321 trial demonstrated that pirtobrutinib, a third-generation noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved progression-free survival and delayed the need for subsequent therapy in patients previously treated with covalent BTK inhibitors. 1 The findings ...

Areas covered: This review describes the use of BTK inhibitors and BCL2 inhibitors in the treatment of naive and relapsed or refractory CLL, with particular attention to the mechanisms of resistance. It also addresses the management of double-refractory patients, and …

Nov 5, 2024 · In this study, we compare the real-world outcomes of pts with CLL, including those with TP53D, treated in the 1L setting with either BTKi or BCL2i therapy. Methods. This study utilized the nationwide Flatiron Health electronic health record-derived de-identified database.

Dec 9, 2022 · Patients with chronic lymphocytic leukemia (CLL) refractory to covalent BTK and BCL2 inhibitors have a new unmet clinical need. Standard treatment options are able to obtain only limited and short-lasting disease control associated with reduced overall survival, and thus these patients have become ideal candidates for enrollment in clinical trials.

Apr 4, 2022 · The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and …

Dec 8, 2024 · A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD ...

In this article, we update our last review of the topic 1, covering the major and practice-changing therapeutic advances in CLL over the last 3 years with a focus on the BTK inhibitors and venetoclax. A comprehensive review on the treatment of CLL was recently published 2.

Nov 18, 2021 · Our results suggest that the Bcl-2 inhibitor venetoclax, in combination with the BTK inhibitor ibrutinib, is highly effective in the treatment of a particularly aggressive DLBCL subtype...

Nov 4, 2021 · In an effort to design a more effective, time-limited regimen, BTK inhibitors have now been combined with venetoclax, with or without obinutuzumab; these combination regimens capitalize on the potentially synergistic effects of BTK and BCL-2 inhibitors.